CSS
HRTX icon

Cubist Systematic Strategies’s Heron Therapeutics HRTX Stock Holding History

Cubist Systematic Strategies’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-56,282
Closed -$156K – 3430
2024
Q1 		$156K Buy
56,282
+2,660
+5% +$6.69K ﹤0.01% 3163
2023
Q4 		$91.2K Buy
+53,622
New +$59K ﹤0.01% 3193
2023
Q3 		– Sell
-35,258
Closed -$40.9K – 3593
2023
Q2 		$40.9K Buy
35,258
+8,020
+29% +$14.3K ﹤0.01% 3119
2023
Q1 		$41.1K Sell
27,238
-323,243
-92% -$809K ﹤0.01% 3595
2022
Q4 		$876K Sell
350,481
-15,294
-4% -$49.3K 0.01% 2579
2022
Q3 		$1.54M Buy
365,775
+322,975
+755% +$1.26M 0.01% 2245
2022
Q2 		$119K Sell
42,800
-70,197
-62% -$282K ﹤0.01% 3904
2022
Q1 		$646K Sell
112,997
-4,434
-4% -$32.4K 0.01% 2370
2021
Q4 		$1.07M Buy
117,431
+30,286
+35% +$309K 0.01% 1858
2021
Q3 		$932K Buy
87,145
+50,141
+136% +$610K 0.01% 1579
2021
Q2 		$574K Sell
37,004
-815
-2% -$13K 0.01% 1916
2021
Q1 		$613K Buy
37,819
+29,477
+353% +$525K 0.01% 1845
2020
Q4 		$177K Sell
8,342
-4,267
-34% -$74.2K ﹤0.01% 2281
2020
Q3 		$187K Sell
12,609
-3,192
-20% -$49.8K ﹤0.01% 2150
2020
Q2 		$232K Sell
15,801
-149,058
-90% -$2.45M ﹤0.01% 1968
2020
Q1 		$1.94M Buy
164,859
+56,890
+53% +$1.07M 0.05% 480
2019
Q4 		$2.54M Buy
+107,969
New +$2.39M 0.05% 617
2019
Q2 		– Sell
-14,566
Closed -$356K – 2503
2019
Q1 		$356K Buy
+14,566
New +$381K 0.01% 1400
2018
Q4 		– Sell
-10,690
Closed -$338K – 2160
2018
Q3 		$338K Buy
10,690
+6,799
+175% +$253K 0.02% 1085
2018
Q2 		$151K Buy
+3,891
New +$124K 0.01% 1441
2018
Q1 		– Sell
-17,395
Closed -$315K – 1934
2017
Q4 		$315K Buy
+17,395
New +$284K 0.02% 1218
2015
Q4 		– Sell
-7,722
Closed -$188K – 1834
2015
Q3 		$188K Buy
+7,722
New +$257K 0.01% 1493
2015
Q2 		– Sell
-2,900
Closed -$42K – 1907
2015
Q1 		$42K Buy
+2,900
New +$32.7K ﹤0.01% 1773

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Cubist Systematic Strategies's HRTX Position: Q2 2024 in Review

Cubist Systematic Strategies sold out of Heron Therapeutics (HRTX) in Q2 2024, closing a stake of 56,282 shares — an estimated $156K sold.

Cubist Systematic Strategies first reported a position in HRTX in Q1 2015 and held it in 23 quarters. The position peaked at $2.54M in Q4 2019. 190 funds tracked by Wall St. Rank hold HRTX as of Q2 2024.

  • Cubist Systematic Strategies reported no remaining Heron Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 56,282 Heron Therapeutics shares in Q2 2024, an estimated $156K.
  • Cubist Systematic Strategies first reported a position in Heron Therapeutics in Q1 2015 and held it in 23 quarters.
  • Cubist Systematic Strategies's Heron Therapeutics position peaked at $2.54M in Q4 2019.
  • 190 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2024.

Based on Cubist Systematic Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.